News and Updates

The recipient of gene-edited islets to evade the immune system is making insulin without the use of immunusuppresives.

While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures and improving everyday life with T1D.   This wouldn’t have been possible without each and every one of you and your continued support of our mission as we drive toward cures for T1D.   Here are the […]

Meet Aiedan, a participant in the T1D RELAY clinical trial that aims to preserve insulin production in those newly diagnosed with type 1 diabetes.

Since 2014, Alecia Wesner has participated in numerous T1D clinical trials, many of which were early artificial pancreas system trials.

Vertex announced the first stem cell-derived islet therapy is entering a phase 3 clinical trial for type 1 diabetes.

A novel immune therapy called tegoprubart made by Eledon Pharmaceuticals and being tested in kidney transplant patients has the potential to help beta cell transplants survive in people with type 1 diabetes (T1D) with fewer side effects. The first data from this Breakthrough T1D-funded study suggests it does. The study was presented at the 5th […]

Here is Aaron J. Kowalski, Ph.D., C with the key takeaways from the conference and below is a written summary of Breakthrough T1D highlights.

A new publication provides more evidence for C-peptide as a validated surrogate to predict clinical benefits of disease-modifying therapies in T1D.

The true story of how Tzield (teplizumab), the first disease-modifying therapy approved for use in delaying type 1 diabetes (T1D) onset, made it to market.

Leading researchers gathered for the ATTD meeting, which featured more than 50 studies presented by Breakthrough T1D-funded researchers.